Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):75–82. doi: 10.1097/QAI.0000000000000710

Table 3.

Incidence of ART eligibility by study group and follow up- interval (ITT analysis)

Intervention
(PSCB)		 Standard of
care (SOC)		 Unadjusted
IRR(95% CI)		 Adj IRR*
(95% CI)		 p value
0-6 month follow-up interval
0-6 months follow-up
Number at risk 535 527
Incident events/100 person yrs 36/277 (13.0) 43/289 (14.9) 0.87(0.57,1.34) 0.83 (0.57,1.20) 0.324
6-12 months follow-up
Number at risk 485 480
Incident events/100 person yrs 47/209 (22.5) 44/206 (21.4) 1.05(0.70,1.57) 1.02 (0.68,1.53) 0.935
0-12 months follow-up
Number at risk 574 564
Incident events/100 person yrs 83/547(15.2) 87/558(15.6) 0.97(0.74,1.29) 1.00 (0.77,1.31 ) 0.946
*

Adjusted for age, sex, occupation and baseline CD4 count